Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.
Rousel J, Saghari M, Pagan L, Nădăban A, Gambrah T, Theelen B, de Kam ML, Haakman J, van der Wall HEC, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, Bouwstra JA, Rissmann R, van Doorn MBA. Rousel J, et al. Among authors: feiss gl. Int J Mol Sci. 2023 Sep 20;24(18):14315. doi: 10.3390/ijms241814315. Int J Mol Sci. 2023. PMID: 37762625 Free PMC article. Clinical Trial.
Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition.
Rousel J, Nădăban A, Saghari M, Pagan L, Zhuparris A, Theelen B, Gambrah T, van der Wall HEC, Vreeken RJ, Feiss GL, Niemeyer-van der Kolk T, Burggraaf J, van Doorn MBA, Bouwstra JA, Rissmann R. Rousel J, et al. Among authors: feiss gl. Exp Dermatol. 2024 Jan;33(1):e14952. doi: 10.1111/exd.14952. Epub 2023 Nov 16. Exp Dermatol. 2024. PMID: 37974545
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.
Niemeyer-van der Kolk T, van der Wall H, Hogendoorn GK, Rijneveld R, Luijten S, van Alewijk DCJG, van den Munckhof EHA, de Kam ML, Feiss GL, Prens EP, Burggraaf J, Rissmann R, van Doorn MBA. Niemeyer-van der Kolk T, et al. Among authors: feiss gl. Clin Transl Sci. 2020 Sep;13(5):994-1003. doi: 10.1111/cts.12792. Epub 2020 May 1. Clin Transl Sci. 2020. PMID: 32315497 Free PMC article. Clinical Trial.
Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions.
Rijsbergen M, Rijneveld R, Todd M, Feiss GL, Kouwenhoven STP, Quint KD, van Alewijk DCJG, de Koning MNC, Klaassen ES, Burggraaf J, Rissmann R, van Poelgeest MIE. Rijsbergen M, et al. Among authors: feiss gl. Br J Clin Pharmacol. 2020 Nov;86(11):2133-2143. doi: 10.1111/bcp.14181. Epub 2020 Sep 28. Br J Clin Pharmacol. 2020. PMID: 31755993 Free PMC article. Clinical Trial.
Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis.
van den Munckhof EHA, Niemeyer-van der Kolk T, van der Wall H, van Alewijk DCJG, van Doorn MBA, Burggraaf J, Buters TP, Becker MJ, Feiss GL, Quint WGV, van Doorn LJ, Knetsch CW, Rissmann R. van den Munckhof EHA, et al. Among authors: feiss gl. Acta Derm Venereol. 2020 Jan 7;100(1):adv00018. doi: 10.2340/00015555-3373. Acta Derm Venereol. 2020. PMID: 31742645 Free PMC article.